Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artesunate ointment for HSIL VIN 2/3
NCT03792516Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Apr 2019
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of artesunate in vulvar intraepithelial neoplasia (VIN) (3 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Safety and tolerability of artesunate ointment at 15 weeks. Started Apr 2019; status: completed.
02
Drugs
artesunate
03
Conditions
vulvar intraepithelial neoplasia (VIN)
Beyond the preview
Go deeper on NCT03792516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03792516.